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Screening for Cardiovascular Risk
in Asymptomatic Patients
Jeffrey S. Berger, MS, MS,*† Courtney O. Jordan, MD,‡ Donald Lloyd-Jones, MD, SCM,§
Roger S. Blumenthal, MD
New York, New York; Philadelphia, Pennsylvania; Minneapolis, Minnesota; Chicago, Illinois;
and Baltimore, Maryland
Cardiovascular disease is the number 1 cause of death in the western world and 1 of the leading causes of
death worldwide. The lifetime risk of atherosclerotic cardiovascular disease (CVD) for persons at age 50 years,
on average, is estimated to be 52% for men and 39% for women, with a wide variation depending on risk factor
burden. Assessing patients’ cardiovascular risk may be used for the targeting of preventive treatments of individ-
ual patients who are asymptomatic but at sufficiently high risk for the development of CVD. Risk stratifying pa-
tients for CVD remains challenging, particularly for those with low or intermediate short-term risk. Several algo-
rithms have been described to facilitate the assessment of risk in individual patients. We describe 6 risk
algorithms (Framingham Risk Score for coronary heart disease events and for cardiovascular events, Adult Treat-
ment Panel III, SCORE [Systematic Coronary Risk Evaluation] project, Reynolds Risk Score, ASSIGN [Assessing
Cardiovascular Risk to Scottish Intercollegiate Guidelines Network/SIGN to Assign Preventative Treatment], and
QRISK [QRESEARCH Cardiovascular Risk Algorithm]) for outcomes, population derived/validated, receiver-
operating characteristic, variables included, and limitations. Areas of uncertainty include 10-year versus lifetime
risk, prediction of CVD or coronary heart disease end points, nonlaboratory-based risk scores, age at which to
start, race and sex differences, and whether a risk score should guide therapy. We believe that the best high-risk
approach to CVD evaluation and prevention lies in routine testing for cardiovascular risk factors and risk score
assessment. We recommend that health care providers discuss the global cardiovascular risk and lifetime car-
diovascular risk score assessment with each patient to better explain each patient’s future risk. Appropriate in-
tervention, guided by risk assessment, has the potential to bring about a significant reduction in population lev-
els of risk. (J Am Coll Cardiol 2010;55:1169–77) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.09.0664
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56-year-old woman without any cardiovascular symptoms
omes to your office to establish care. She does not smoke
urrently, but she reports smoking until 4 years ago when
er sister at age 54 had an ischemic stroke. There is no
amily history of myocardial infarction (MI) or sudden
ardiac death. Her resting blood pressure is 138/76 mm Hg,
asting glucose is 109 mg/dl (6 mmol/l), total cholesterol is
10 mg/dl (5.4 mmol/l), high-density lipoprotein (HDL) is
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ccepted September 14, 2009.2 mg/dl (1.1 mmol/l), and triglyceride level is 201 mg/dl
2.3 mmol/l). She is physically inactive, and her body mass
ndex (the weight in kilograms divided by the square of the
eight in meters) is 31. She has never taken any medication.
he is asking what is her risk for a future cardiovascular
isease (CVD) event?
he Clinical Problem
ardiovascular disease is the number 1 cause of death in the
estern world and 1 of the leading causes of death world-
ide. An estimated 1 in 3 American adults have 1 or more
ypes of atherosclerotic vascular disease (coronary heart
isease [CHD], cerebrovascular disease, or peripheral artery
isease) (1). The lifetime risk of atherosclerotic CVD for
ersons at age 50 years, on average, is estimated to be 52%
or men and 39% for women, with a wide variation
epending on risk factor burden (2). Assessing a patient’s
ardiovascular risk may be used for the targeting of preven-
ive treatments of individual patients who are asymptomatic
ut at sufficiently high risk for the development of CVD (3).
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Screening for Cardiovascular Risk March 23, 2010:1169–77Several algorithms have been
described to facilitate the assess-
ment of risk in individual pa-
tients. Most risk scores have in-
cluded age, sex, blood pressure
level, smoking status, diabetes
mellitus, and lipid values. Several
recent risk scores have proposed
including additional risk factors,
including use of antihyperten-
sive therapy, C-reactive protein
(CRP), family history of prema-
ture CHD, social deprivation, and
hemoglobin A1c.
Although obesity is a risk factor,
it is frequently omitted because its
influence is largely mediated
through other cardiovascular risk
factors in the short term (5- to
10-year timeline of most risk esti-
mation algorithms). Chronic kid-
ney disease, another apparent
risk factor for the development of
CVD, has yet to be incorporated
into a risk scoring method. Most
persons in the general population
have 1 or more risk factors for
CVD (4). To demonstrate the
importance of cardiovascular risk
factors, the INTERHEART
study, a case-control study of 52
countries, noted that optimiza-
ion of 9 easily measured and potentially modifiable risk
actors could potentially result in a 90% reduction in the risk
f an initial acute MI (5).
Cardiovascular prevention strategies may vary in benefit
epending on the underlying level of cardiovascular risk.
he absolute reduction in risk is important to estimate, to
dequately assess the risk versus benefit of any prevention
trategy. If the relative risk reduction is equal across risk
trata, the absolute reduction would be greater in a high-risk
ohort than in a low-risk cohort. For this reason, it is very
mportant to accurately estimate the cardiovascular risk.
epending on the risk score used, the same patient may be
ategorized into a different level of risk. However, one must
ot confuse the quantitative value provided by the risk score
nd the largely arbitrary labels put on those by prevention
lgorithms. For example, although 9.8% may be lower risk
nd 10.2% may be intermediate risk, these scores do not
iffer markedly, yet that is the magnitude of most reclassi-
cation that happens when comparing risk scores.
In this context, different risk scores have been proposed as
otential means for quantifying the assessment of risk in
symptomatic persons (Table 1). Importantly, implement-
ng a “high-risk” strategy alone is unlikely to reduce the
Abbreviations
and Acronyms
ABI  ankle-brachial index
ASSIGN  Assessing
Cardiovascular Risk to
Scottish Intercollegiate
Guidelines Network/SIGN
to Assign Preventative
Treatment
ATP  Adult Treatment
Panel
CHD  coronary heart
disease
CRP  C-reactive protein
CVD  cardiovascular
disease
FRS  Framingham risk
score
HDL-C  high-density
lipoprotein cholesterol
hsCRP  high-sensitivity
C-reactive protein
IMT  intima media
thickness
LDL-C  low-density
lipoprotein cholesterol
MI  myocardial infarction
QRISK  QRESEARCH
Cardiovascular Risk
Algorithm
SCORE  Systematic
Coronary Risk Evaluationverall prevalence of CVD because the “lower-risk” popu- iation, which by sheer number is the largest group affected
ith heart disease, would comprise most events. Thus, for
ocietal purposes, it is important to implement both high-
isk prevention and population-based approaches.
trategies and Evidence
ramingham risk score (FRS). The Framingham Heart
tudy is a landmark achievement (6), well known for its
0-year risk score for prediction of CHD events in
symptomatic patients (7). Risk factors used in Framing-
am scoring include age, sex, total cholesterol, high-
ensity lipoprotein cholesterol (HDL-C), blood pressure,
nd cigarette smoking. Importantly, the FRS is easy to
pply and clinically relevant. The FRS for hard CHD
vents has been incorporated into several guidelines for
VD prevention (3,8,9) and been used to guide treat-
ent of risk factors (Table 1).
The FRS was adapted and then incorporated into the
ational Cholesterol Education Program Expert Panel on
etection, Evaluation, and Treatment of High Blood Cho-
esterol in Adults (Adult Treatment Panel III [ATP III])
or use in their recommendations for screening for and
reatment of dyslipidemia (3). Although the FRS has been
alidated in many populations, including Caucasian Amer-
cans and African Americans (10), its accuracy is somewhat
imited among some European and Asian populations, and
ome risk markers are not incorporated. In a systematic
eview of 27 studies using the Framingham scoring system,
he predicted-to-observed ratios ranged from an underpre-
iction of 0.43 in a high-risk population to an overpredic-
ion of 2.87 in a low-risk population (11). The FRS has
een evaluated in the largest number of diverse settings, and
any of these problems are likely to be relevant to the other
isk scores.
In addition to the coronary event risk score, the FRS has
een developed for a composite of all atherosclerotic CVD
CHD composite including angina, cerebrovascular events,
eripheral artery disease, and heart failure) (2) as well as
ndividual risk scores for each specific components, includ-
ng peripheral artery disease (12), stroke (13), and heart
ailure (14). Risk scores have also been developed for
ifetime risk (15,16) and 30-year risk (17) as opposed to
0-year risk. These latter scores require further validation.
TP III. The ATP III document updated clinical guide-
ines for cholesterol testing and management (3). The ATP
II identified 3 categories of risk that modify the goals and
odalities of low-density lipoprotein cholesterol (LDL-C)
owering therapy on the basis of CHD as an end point. The
ategory of highest risk (20% per 10 years) consists of
HD and CHD risk equivalents (atherosclerotic disease of
ther arterial beds and diabetes mellitus). The LDL-C goal
s 100 mg/dl.
The second category consists of multiple (2) risk factors
nd the LDL-C goal is 130 mg/dl. The major risk factors
nclude cigarette smoking, blood pressure 140/90 mm Hg
Characteristics of the Various Cardiovascular Risk ScoresTable 1 Characteristics of the Various Cardiovascular Risk Scores
Study (Ref. #) Variables Included Outcomes Population Derived Population Validated ROC Limitations
FRS (6,7) Age, sex, BP, smoking, use of HTN
medications, TC, and HDL
CHD (angina, MI, sudden
death)
U.S. white men and women,
ages 30–62 yrs
Men, women, blacks, Europe,
Mediterranean, and Asia
0.7744 (w) 0.7598 (m) Age 30 yrs, 65 yrs, Japanese-
American men, Hispanic men,
Native-American women, LVH,
DM, and severe HTN
Global cardiovascular
risk (2)
Age, sex, SBP, smoking, TC, HDL,
DM, and use of HTN medications
CHD, stroke, CHF, or PVD U.S. white men and women,
ages 30–74 yrs
Framingham offspring 0.793 (w) 0.763 (m) Mainly white
SCORE (20) Age, sex, smoking, either TC or
TC/HDL ratio, broken up into
areas of high and low CVD risk
Fatal CV events European men and women,
ages 45–64 yrs
Europe 0.71–0.84 No nonfatal events, “single” risk factor
measurements made, rather than
“usual”
ASSIGN (23) Age, sex, SBP, TC, HDL, family
history, social deprivation
CV death, CHD
admission, CABG, or
PTCA
Scotland men and women,
ages 30–74 yrs
Scotland 0.7841 (w) 0.7644 (m) Marginally better than Framingham,
still overestimated risk
Reynolds (21) Age, SBP, smoking, total
cholesterol, HDL, hsCRP,
family history, hgbAIc
if DM
MI, stroke, coronary
revascularization, or
CV death
U.S. women, age 45 yrs U.S. women 0.808 (w) Mainly white, all women,
socioeconomic status not
generalizable, BP, weight, and family
history, all taken by self-report
QRISK (24,25) Age, sex, SBP, smoking, ratio of
TC/HDL, family history, use of
HTN medications, BMI, social
deprivation
MI, CHD, stroke, TIA United Kingdom men and
women, ages 35–74 yrs
United Kingdom 0.7879 (w) 0.7674 (m) “Home advantage,” data validated
from same population it was
originally derived
Reynolds, men (22) Age, sex, SBP, smoking, total
cholesterol, HDL, hsCRP,
family history, hgbAIc if DM
MI, stroke, coronary
revascularization, or
CV death
U.S. men, ages 50–80 yrs U.S. men 0.7–0.714 (m) Mainly white, middle-aged,
socioeconomic status and access to
care not generalizable, self-reported
with family history
ASSIGN Assessing Cardiovascular Risk to Scottish Intercollegiate Guidelines Network/SIGN to Assign Preventative Treatment; BMI body mass index; BP blood pressure; CABG coronary artery bypass graft surgery; CHD coronary heart disease; CVD cardiovascular
disease; DM  diabetes mellitus; FRS  Framingham risk score; HDL  high-density lipoprotein; hgb  hemoglobin; hsCRP  high-sensitivity C-reactive protein; HTN  hypertension; LVH  left ventricular hypertrophy; m  men; MI  myocardial infarction; PTCA 
percutaneous transluminal coronary angiography; ROC receiver-operating characteristic; QRISK QRESEARCH Cardiovascular Risk Algorithm; SBP systolic blood pressure; SCORE Systematic Coronary Risk Evaluation; TC total cholesterol; TIA transient ischemic
attack; w  women.
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Screening for Cardiovascular Risk March 23, 2010:1169–77r receiving antihypertensive medication, low HDL-C,
amily history of premature CHD, and age 45 years in
en or 55 years in women. The ATP III risk algorithm
tratifies these persons into those with 10-year risk for
HD of 20%, 10% to 20%, and 10%. The third
ategory consists of persons with 0 to 1 risk factor and the
DL-C goal of 160 mg/dl.
In 2004, a modification of the risk categories was pro-
osed (18); the multiple risk factor category was divided into
moderately high risk group (2 risk factors and 10-year
HD risk 10% to 20%), and a moderate risk group (2 risk
actors and 10-year CHD risk 10%). For the moderately
igh risk group, there is an optional LDL-C goal of 100
g/dl largely based on the ASCOT (Anglo-Scandinavian
ardiac Outcomes Trial) of lipid lowering in adults with
reated hypertension (19).
he SCORE project. The SCORE (Systematic Coronary
isk Evaluation) project intended to provide better predic-
ive accuracy for European patients. The SCORE system
as derived from data from 200,000 patients pooled from
2 European cohort studies (20). The SCORE system
stimates the 10-year risk of a first fatal atherosclerotic event
ncluding heart attack, stroke, or aortic aneurysm. This is
ignificant because it estimates the risk for any fatal athero-
clerotic event, but is limited in that it does not consider
onfatal events.
Risk factors used in the SCORE system include age, sex,
otal cholesterol, total cholesterol to HDL-C ratio, systolic
lood pressure, and cigarette smoking. A unique aspect of
he SCORE system is that it has separate risk scores for
igher risk and lower risk regions of Europe. Nevertheless,
he predictive value of the SCORE system was high in each
omponent study cohort from Europe. There are now
ultiple country-specific versions of the SCORE system.
eynolds risk score. The Reynolds risk score was initially
esigned to develop and validate an algorithm for global
ardiovascular risk in healthy women (21). Thirty-five
actors were assessed among 25,000 initially healthy
omen health professionals enrolled in a clinical trial in the
.S. The Reynolds risk score estimates the 10-year risk of
ardiovascular events, a composite of MI, ischemic stroke,
oronary revascularization, and cardiovascular death.
Of note, risk factors such as blood pressure and body
eight were not directly measured but were self-reported in
ategories, which may have diminished some of their utility
s predictive variables, allowing opportunities for other
ovariates to add predictive utility. Additionally, the risk
core was validated from the same population it was derived.
The authors provided 2 models: a best-fitting model and
clinically simplified model (the Reynolds risk score). The
eynolds risk score was composed of age, systolic blood
ressure, hemoglobin A1c if diabetic, smoking, total and
DL-C, C-reactive protein measured by a high-sensitivity
ssay (hsCRP), and parental history of MI before age 60
ears. In contrast to the FRS and SCORE system, the aeynolds score evaluated and incorporated the risk factors
f parental history of premature CHD and hsCRP.
Recently, the Reynolds risk score, using male-specific
quations, was applied to healthy nondiabetic men with
ood results (22). Similar to women, the authors showed
hat the addition of hsCRP and parental history of MI
efore age 60 years improved global cardiovascular risk
rediction and reclassification of risk as compared with the
raditional FRS employed in the ATP III in a population of
ale health professionals enrolled in a clinical trial.
he ASSIGN risk score. Using a representative database
rom Scotland, the ASSIGN (Assessing Cardiovascular
isk to Scottish Intercollegiate Guidelines Network/SIGN
o Assign Preventative Treatment) risk score was developed
23). This score was derived from men and women ages 30
o 74 years and free of symptomatic CVD. The ASSIGN
core estimates the 10-year risk of CVD, including cardio-
ascular death or any hospital discharge diagnosis of CHD,
erebrovascular disease, or coronary artery intervention.
Traditional risk factors, including number of cigarettes
moked, plus social deprivation and family history, but not
besity, were significant factors in this risk score. The
SSIGN scoring system was novel because the authors
ncluded an index of social status, which may account for
ocial gradients in disease.
RISK risk score. The QRISK (QRESEARCH cardio-
ascular risk algorithm) CVD risk score was derived from a
arge United Kingdom primary care population (24,25).
he derivation cohort consisted of 1.3 million subjects ages
5 to 74 years free from diabetes and CVD. The QRISK
core estimates the 10-year risk of CVD, including MI,
HD, stroke, and transient ischemic attack. Risk factors
ere age, sex, smoking status, systolic blood pressure, ratio
f total to HDL-C, body mass index, family history of
HD, a measure of social deprivation, and treatment with
ntihypertensive agent.
This was the first study to use data from a general practice
opulation and not use an observational study in a pre-
efined cohort. Both the QRISK and ASSIGN risk scores
nclude social deprivation, an important step in acknowl-
dging inequalities in cardiovascular risk. A major limitation
f this risk score was that it was validated from the same
opulation it was derived from.
ariables With Incremental Prediction
lthough risk-scoring models can improve the prediction of
isk, their adoption into clinical practice is poor. Moreover,
hey are derived from populations and applied to patients.
owever, this is how we practice and apply medicine; the
remise of evidence-based medicine is to apply average
ffects observed in clinical trials to patients in prescribing
reatments and preventive therapies. The incorporation of
oninvasive tests as indicators of asymptomatic atheroscle-
osis, such as the ankle-brachial index (ABI), coronary
rtery calcium, carotid artery intima media thickness (IMT),
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March 23, 2010:1169–77 Screening for Cardiovascular Risknd electrocardiographic exercise testing, has been proposed
26,27). Many of these noninvasive tests are touted as a
otential means for improving and perhaps simplifying the
stimation of cardiovascular risk in asymptomatic subjects.
owever, controversy exists regarding screening for under-
ying CVD (28,29).
The ABI, which is the ratio of systolic pressure at the
nkle to that in the arm, is quick and easy to measure and is
n indicator of lower extremity peripheral arterial disease,
hich is overwhelmingly due to atherosclerosis. In a recent
ollaboration of 16 international cohorts (30), the ABI
rovided independent risk information over and above the
RS, and a low ABI approximately doubled the risk of total
nd cardiovascular mortality and major coronary events
cross all FRS categories. The authors of that analysis
ropose a new risk equation incorporating the ABI with
RS markers and are intending to develop and validate such
model.
Computed tomography can noninvasively detect and
uantify coronary artery calcification. The presence and
xtent of coronary artery calcification would seem to be a
ery useful risk factor as it essentially visualizes coronary
therosclerosis. A report from the MESA (Multi-Ethnic
tudy of Atherosclerosis) cohort found a strong association
etween coronary calcification and incident CHD, with an
djusted relative hazard for coronary events between 3.6 and
.7, depending on the amount of calcification (31). The
-index (discriminant accuracy) for risk factors plus calcium
core was excellent at 0.83 for MI and death, and 0.82 for all
HD events (p  0.01 in comparison with risk factors
lone, 0.79 and 0.77, respectively) (31).
Carotid artery IMT is thought to be a marker for early
therosclerosis. It has been used in large-scale population
tudies, but the measurements are very operator dependent.
everal studies have noted a moderate, graded association
etween carotid IMT and the presence of coronary athero-
clerosis and the risk of future cardiovascular events (32).
owever, much of the excess risk is attenuated when
djusted for traditional risk factors. Furthermore, IMT
esting is only available at select centers, and its measure-
ent has considerable interobserver variability when it is
sed in routine clinical practice.
An abnormal electrocardiographic exercise test is associ-
ted with an increased risk of MI and sudden cardiac death
33). The exercise test provides substantial diagnostic and
rognostic value beyond simple ST-segment changes, in-
luding exercise capacity, heart rate recovery, presence or
bsence of arrhythmias, and hemodynamic responses.
A cohort study of asymptomatic patients followed up for
20 years found that exercise testing was strongly predictive
f cardiovascular death, incremental to the FRS, and across
RS risk categories with 20% risk of a CHD event over
0 years (27). In a report from the Framingham Heart
tudy, exercise testing provided additional prognostic infor-
ation in age- and FRS-adjusted models, particularly lmong those in the highest risk group (10-year predicted
HD risk of 20%) (34).
reas of Uncertainty
0-year and lifetime risk. Recent emphasis has been
laced on lifetime risk of developing CVD. Among people
ree of CVD at age 50 years, 50% of men and nearly 40%
f women will have CVD during their lifetime. Should we
lace more emphasis on lifetime risk or 10-year risk esti-
ates? Patients who are 50 years of age or younger may have
very high lifetime cardiovascular risk, which may be
menable to risk factor reduction, but may be considered to
e at low risk because they have a low 10-year cardiovascular
isk (due to the weighting of age in 10-year risk equations).
Lifetime risk may allow policy makers to better promote
ublic interest in prevention, screening, and treatment of
VD, especially in younger people who have high long-
erm risks. In addition, lifetime risk can potentially guide
he allocation of resources to improve public health and
reventive services for CVD, and be useful in the design of
pidemiological studies. Nevertheless, estimates of short-
erm (10-year) risk are useful for the identification of
atients who need aggressive risk reduction in the near term.
his level of risk may justify aggressive pharmacological
gents and should be evaluated balancing efficacy, costs, and
afety of therapy.
VD versus CHD. What end point should be evaluated?
urrently, there are risk scores for MI, stroke, peripheral
rtery disease, atrial fibrillation, cardiac revascularization,
nd more. There is also a composite risk score for all
therosclerotic CVD (CHD composite including angina,
erebrovascular events, peripheral artery disease, and heart
ailure) (2).
Although many studies are designed using “hard end
oints” (MI, stroke, and death), the inclusion of “softer” or
ore subjective end points (such as angina, claudication,
eart failure, and revascularizations) are important from a
atient’s perspective and policy standpoint. Patients and
ealth care policy makers may benefit from putting re-
ources into avoiding these softer end points to risk stratify,
ounsel, and potentially treat with pharmacologic therapy
e.g., aspirin and statin therapy) those patients earlier than
dvocated by existing national guidelines in order to reduce
he risk of a hard end point in the future.
onlaboratory-based risk score. Because of the limited
esources available in certain areas of the world, finding
ow-cost strategies for risk scores is essential. Almost every
isk score contains some laboratory test as a risk marker. In
n attempt to simplify risk prediction, Framingham study
2) and NHANES (National Health and Nutrition Exam-
nation Survey) (33) data were used to develop an assess-
ent tool using measurements readily available at the clinic
r office.
Gaziano et al. (35) evaluated whether a risk score withoutaboratory testing could predict CVD as effectively as 1 that
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Screening for Cardiovascular Risk March 23, 2010:1169–77ncludes laboratory testing. The nonlaboratory-based model
sed the same risk factors from the FRS but excluded HDL,
nd total cholesterol was replaced with body mass index.
he authors demonstrated an almost identical ability to
ccurately discriminate CVD from a nonlaboratory-based
isk score (35). For that reason, use of a nonlaboratory-
ased risk score should be considered in all areas where
aboratory data are unavailable, and future studies should
ssess the predictive value of laboratory versus nonlaboratory
ased risk assessment.
ge at which to start. Many of these risk scores have not
een evaluated or validated in younger populations.
hese observations are important because younger sub-
ects may have a very high lifetime cardiovascular risk,
hich may be amenable to risk factor reduction, but they
ay be considered to be at low risk because they have a
ow 10-year risk. A study of risk prediction in young
dults noted an inability of the FRS to classify patients
40 years of age at high 10-year risk despite substantial
isk factor burden (36). In fact, younger patients are at
ower risk, but this gives an incomplete picture to them
egarding long-term risk and hampers risk communica-
ion, and likely diminishes motivation and adherence to
ecommendations. Moreover, with the ongoing obesity
pidemic continuing to start at younger ages and the
ontinued lack of physical activity in many young adults,
here are likely many young adults that are at heightened
ong-term risk.
Given that the goal of risk stratification is to avoid bad
linical outcomes by starting behavioral change and medical
herapy earlier, it is reasonable to screen when clinicians
ecome concerned that a patient is at increased risk. Recent
ata suggest that younger adults (age 50 years) with a
ow-10 year risk and high lifetime risk of 39% (at least 1
levated risk factor that can be treated) have a greater
ubclinical disease burden and greater incidence of athero-
clerotic progression compared with patients with low
0-year and lifetime risk (37). This suggests a potential
enefit of aggressive prevention efforts for younger age
atients with low short-term risk but high lifetime predicted
isk.
ace and/or sex differences. Absolute risks in any risk
core may differ according to the set of risk factors present
n a given population, for example, those of different racial
r ethnic characteristics. This difference may be due to
ifferential susceptibility to established risk factors along
ith exposure to “emerging” risk factors. Several studies
ave suggested that the FRS overestimates the risk of CHD
vents in Japanese-American and Hispanic men, in Native
merican women, and in European and Asian populations
10,38–40).
A 1999 workshop convened by the National Heart,
ung, and Blood Institute to evaluate the Framingham
unctions in non-Framingham populations noted compara-
le FRS estimates for CHD between white and black U.S.
opulations (40). However, blood pressure should ideally be miven extra weight in black men and women. The authors
lso concluded that differences extend to various ethnic
roups and will require adjustment of absolute risk estimates
ased on ethnicity using simple calibration adjustments to
ccount for different underlying rates of disease incidence
nd prevalence of risk factors.
Sex-stratified prediction scores in each of the scoring
ethods discussed in the preceding text illustrate the
ignificant differences between women and men. An impor-
ant sex difference is the 10-year delay in the onset of CVD
n women, which remains incompletely understood. The
ifference between women and men particularly stands out
or which end point to analyze. Women are at higher risk
or stroke earlier in life, whereas men are at higher risk for
I. Furthermore, primary prevention trials of aspirin dem-
nstrated that aspirin was effective in the reduction of stroke
or women and MI in men (41,42).
Nevertheless, in American College of Cardiology/
merican Heart Association recommendations for aspirin,
urrent guidelines tend to use the 10-year FRS for CHD as
guide to treat or not to treat with aspirin therapy. It seems
hat women, who derive their benefit from aspirin princi-
ally by reducing the risk of stroke, should use a risk score
ncluding the risk of stroke factored into the treatment
ecision. In fact, the recent U.S. Preventive Services Task
orce recommends aspirin for men based on the risk for
HD whereas aspirin for women should be based on the
isk for stroke (8).
hould Risk Estimates Guide Therapy?
isk stratification tools can and should be used in conjunc-
ion with commonly practiced medical guidelines. The
ecision to use or not to use a certain medication for
ardiovascular prevention depends, in part, on the initial risk
or CVD in that person. Thus, decisions about aspirin
herapy for primary prevention should consider the overall
isks for CVD (and potential harm of aspirin).
Available tools, as described above, provide estimates of
bsolute cardiovascular risk allowing for an informed deci-
ion between the patient and the medical care provider.
nfortunately, risk scoring for proper evaluation of poten-
ial side effects (e.g., major bleeding from aspirin use or
yperkalemia from blockade of the renin/angiotensin sys-
em) of certain medications is not available. Only after
roper assessment for both benefit and risk can optimal
ecisions be made.
Nevertheless, providing a risk score for the development
f CVD should promote a discussion about behavioral
hange and medical therapy that may decrease the likeli-
ood of onset of disease or disease progression. A short- and
ong-term risk stratification tool can be of great benefit in
elping the patient understand their risk and perhaps be a
otivating tool as well.
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March 23, 2010:1169–77 Screening for Cardiovascular Riskuidelines
he assessment of cardiac risk in asymptomatic patients
ithout CVD is increasingly advocated by international
rganizations and by individual risk factor guidelines
3,8,9,18,43,44). Guidelines from the American Heart As-
ociation (9) recommend a 10-year risk assessment begin-
ing at age 40 years and repeated every 5 years (or more
requently if risk factors change). Although no specific risk
core was mandated, the authors supported the Framing-
am 10-year CHD score, while acknowledging its limita-
ions in some race and ethnic groups.
A combined statement from the American Heart Asso-
iation and American College of Cardiology (44) supported
n assessment of risk for adequate primary prevention,
rimarily involving the FRS. In contrast, the European
ociety of Cardiology recommended the SCORE system
43), a 10-year risk score for cardiovascular mortality. The
uthors of all these guidelines express concern that any risk
ssessment is not perfect and should not be used to promote
omplacency. Rather, all patients, regardless of risk, should
e counseled on proper dietary and lifestyle management.
onclusions and Recommendations
or the patient in the case vignette, the estimated risk
aries according to the risk score used (Table 2). The
0-year “hard” risk of CHD (MI/CHD death) is 2%,
hereas the 10-year global cardiovascular risk ranges
rom 6% to 14%. Further adding complexity, her lifetime
isk for CVD is estimated to be 39% (50% if we count her
besity as a major risk factor). Recently, the “heart age”
or “vascular age”) was promoted to better understand the
oncept of risk (2). This 56-year-old woman with abnormal
isk factors has the heart age of a 73-year-old woman with
ormal risk factors. Table 3 estimates the cardiovascular risk
f this patient using stable variables from the 10-year CHD
RS, but modifying other risk factors not calculated in the
RS (e.g., family history, hsCRP, body mass index, and
ocial deprivation).
isk Score of the Patientescribed in Case Vigne teTable 2 Risk Scor of the PatientDescribed in Case Vignette
Risk Score Estimated Risk
Framingham
10-yr CHD risk score 2%
Global CVD score 10%*
Heart age/vascular age 73
Reynolds 6%
SCORE (fatal CVD) 1%–2%†
QRISK 11%
ASSIGN 14%
Lifetime risk for CVD 39%
The risk was 10% in both the full model and the simpler nonlaboratory-based model. †One
ercent if population is in a country with low cardiovascular risk and 2% if in a country with higha
ardiovascular risk.
Abbreviations as in Table 1.The best high-risk approach for CVD evaluation and
revention lies in routine testing for cardiovascular risk
actors and risk score assessment. This approach, while not
erfect, is a valuable tool for identifying a population who
an benefit from preventive treatments demonstrated to be
ffective in clinical trials. We recommend that health care
roviders discuss the 10-year CHD as well as global
ardiovascular risk, and lifetime cardiovascular risk score
ssessment with each patient to better explore each individ-
al patient’s future risk. Use of a global and lifetime
ardiovascular risk score will engage greater numbers of
atients, at an earlier stage of their disease, and highlight the
eed for early and prolonged intervention on risk factors.
ppropriate intervention, guided by risk assessment, has the
otential to bring about a significant reduction in long-term
isk.
Potential risk reduction strategies for this patient include
ggressive lifestyle change, blood-pressure–lowering agents,
holesterol-lowering drugs, and aspirin. We believe that, for
he purpose of deciding whether to start therapy and evaluation
f benefit versus risk, global risk scores should be used.
owever, the validity and applicability of each risk score
ariation in Cardiovascular Risk Calculated on thesis f the Results of Several Pub ishedisk Scores
Table 3
V riation in Cardiovascular Risk Calculated on the
Basis of the Results of Several Published
Risk Scores
Risk Score Estimated Risk
Framingham
10-yr CHD risk score 2%
Reynolds
Negative FH, hsCRP 0.5 mg/l 2%
Negative FH, hsCRP 3.0 mg/l 3%
Negative FH, hsCRP 8.0 mg/l 4%
Positive FH, hsCRP 0.5 mg/l 3%
Positive FH, hsCRP 3.0 mg/l 5%
Positive FH, hsCRP 8.0 mg/l 6%
SCORE (fatal CVD)
Country of low cardiovascular risk 1%
Country of high cardiovascular risk 2%
QRISK
Negative FH, BMI 23 kg/m2 6%
Negative FH, BMI 23–32 kg/m2 6%
Negative FH, BMI 33 kg/m2 7%
Positive FH, BMI 23 kg/m2 10%
Positive FH, BMI 23–32 kg/m2 11%
Positive FH, BMI 33 kg/m2 12%
ASSIGN*
Negative FH, SIMD 10 7%–8%
Negative FH, SIMD 10–29 8%–10%
Negative FH, SIMD 30 10%–15%
Positive HH, SIMD 10 12%–13%
Positive FH, SIMD 10–29 13%–15%
Positive FH, SIMD 30 15%–23%
Lifetime risk for CVD 39%
ASSIGN incorporates SIMD (Scottish Index of Multiple Deprivation) as a risk factor. The SIMD can
ange between 0.54 (least deprived) and 87.6 (most deprived).
FH  family history; other abbreviations as in Table 1.ssessment should be evaluated in future studies, and only
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hether the risk score improves important health outcomes
nd health care expenditures.
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